I have had to add a bit more as some of the addendum to my last post did not attach. I intended to include several papers that argue both sides of the discussion re dx of ischemic and hemorrhagic strokes (even though this is more than beating the hell out of an expired equine life form). As a summary, several indices (such as that of Siriraj and Allen) have reported PPVs ranging from the high 70s to the low 90s. The main point is that these indices have general utility for rapid diagnostic screening and provide a means of establishing "suspicion" (as stated above). Certainly, no one is "lying" regarding utilization of clinical diagnostic criteria in assessing etiology of a given stroke. One obviously will perform a CT or MRI if it is available (again, in many countries it is NOT). In addition, I recalled an interesting paper from a couple of years ago that MAY hold promise for expanding and boosting the sensitivity and PPV of such diagnostic criteria (see below; only have the abstract. The full citation is available for anyone so interested).
One good result of this largely ridiculous discussion is consideration of the updated literature re evaluations of some clinical scoring scales.
Research Article
ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke
Laure Allard[SIZE=-1] 1[/SIZE][SIZE=-1] *[/SIZE], Pierre Lescuyer[SIZE=-1] 1[/SIZE], Jennifer Burgess[SIZE=-1] 1[/SIZE], Kit-Yi Leung[SIZE=-1] 2[/SIZE], Malcolm Ward[SIZE=-1] 2[/SIZE], Nadia Walter[SIZE=-1] 1[/SIZE], Pierre R. Burkhard[SIZE=-1] 3[/SIZE], Garry Corthals[SIZE=-1] 1[/SIZE], Denis F. Hochstrasser[SIZE=-1] 1[/SIZE], Jean-Charles Sanchez[SIZE=-1] 1[/SIZE][SIZE=-1]1[/SIZE]Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, Geneva, Switzerland
[SIZE=-1]2[/SIZE]Proteome Sciences plc, South Wing Laboratory, Institute of Psychiatry, King's College London, London, UK
[SIZE=-1]3[/SIZE]Neurology Department, Geneva University Hospital, Geneva, Switzerland
email: Laure Allard (
[email protected])
[SIZE=-1]*[/SIZE]Correspondence to Laure Allard, Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, CH-1211 Geneva 14, Switzerland
Fax: +41-22-372-73-99
setDOI("ADOI=10.1002/pmic.200300809")
KeywordsApolipoprotein Hemorrhagic stroke Ischemic stroke Plasmatic diagnostic marker
AbstractEarly diagnosis and immediate therapeutic interventions are crucial factors to reduce the damage extent and the risk of death. Currently, the diagnosis of stroke relies on neurological assessment of the patient and neuro-imaging techniques including computed tomography and/or magnetic resonance imaging scan. An early diagnostic marker of stroke, ideally capable to discriminate ischemic from hemorrhagic stroke would considerably improve patient acute management. Using surface-enhanced laser desorption/ionization (SELDI) technology, we aimed at finding new early diagnostic plasmatic markers of stroke. Strong anionic exchange (SAX) SELDI profiles of plasma samples from 21 stroke patients were compared to 21 samples from healthy controls. Seven peaks appeared to be differentially expressed with significant
p values (
p < 0.05). Proteins were stripped from the SAX chips, separated on a one-dimensional electrophoresis (1-DE) gel and stained using mass spectrometry (MS)-compatible silver staining. Following in-gel tryptic digestion, the peptides were analyzed by MS. Four candidate proteins were identified as apolipoprotein CI (ApoC-I), apolipoprotein CIII (ApoC-III), serum amyloid A (SAA), and antithrombin-III fragment (AT-III fragment). Assessment of ApoC-I and ApoC-III levels in plasma samples using a sandwich enzyme-linked immunosorbent assay (ELISA) allowed to distinguish between hemorrhagic (
n = 15) and ischemic (
n = 16) stroke (
p < 0.001). To the best of our knowledge, ApoC-I and ApoC-III are the first reported plasmatic biomarkers capable to accurately distinguish between ischemic and hemorrhagic stroke in a small number of patients. It requires further investigation in a large cohort of patients.